Keeps Biopharma Statistics

Total Valuation

Keeps Biopharma has a market cap or net worth of KRW 200.78 billion. The enterprise value is 246.77 billion.

Market Cap	200.78B
Enterprise Value	246.77B

Important Dates

The last earnings date was Tuesday, November 11, 2025.

Earnings Date	Nov 11, 2025
Ex-Dividend Date	n/a

Share Statistics

Keeps Biopharma has 20.08 million shares outstanding. The number of shares has increased by 1.54% in one year.

Current Share Class	20.08M
Shares Outstanding	20.08M
Shares Change (YoY)	+1.54%
Shares Change (QoQ)	+8.26%
Owned by Insiders (%)	4.13%
Owned by Institutions (%)	4.23%
Float	14.74M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.27
PB Ratio	2.23
P/TBV Ratio	7.05
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-8,705.72
EV / Sales	1.56
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-15.81

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 0.79.

Current Ratio	1.55
Quick Ratio	0.80
Debt / Equity	0.79
Debt / EBITDA	29.15
Debt / FCF	-4.56
Interest Coverage	-0.11

Financial Efficiency

Return on equity (ROE) is 0.30% and return on invested capital (ROIC) is -0.35%.

Return on Equity (ROE)	0.30%
Return on Assets (ROA)	-0.26%
Return on Invested Capital (ROIC)	-0.35%
Return on Capital Employed (ROCE)	-0.53%
Revenue Per Employee	1.45B
Profits Per Employee	-260,057
Employee Count	109
Asset Turnover	0.88
Inventory Turnover	7.19

Taxes

Income Tax	-2.92B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +110.08% in the last 52 weeks. The beta is 1.61, so Keeps Biopharma's price volatility has been higher than the market average.

Beta (5Y)	1.61
52-Week Price Change	+110.08%
50-Day Moving Average	9,760.60
200-Day Moving Average	12,099.30
Relative Strength Index (RSI)	53.29
Average Volume (20 Days)	96,921

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Keeps Biopharma had revenue of KRW 157.75 billion and -28.35 million in losses. Loss per share was -1.48.

Revenue	157.75B
Gross Profit	28.77B
Operating Income	-748.91M
Pretax Income	-2.69B
Net Income	-28.35M
EBITDA	2.44B
EBIT	-748.91M
Loss Per Share	-1.48

Full Income Statement

Balance Sheet

The company has 39.56 billion in cash and 71.22 billion in debt, giving a net cash position of -31.66 billion or -1,577.07 per share.

Cash & Cash Equivalents	39.56B
Total Debt	71.22B
Net Cash	-31.66B
Net Cash Per Share	-1,577.07
Equity (Book Value)	89.95B
Book Value Per Share	3,766.22
Working Capital	39.40B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -9.15 billion and capital expenditures -6.46 billion, giving a free cash flow of -15.61 billion.

Operating Cash Flow	-9.15B
Capital Expenditures	-6.46B
Free Cash Flow	-15.61B
FCF Per Share	-777.46

Full Cash Flow Statement

Margins

Gross margin is 18.24%, with operating and profit margins of -0.47% and -0.02%.

Gross Margin	18.24%
Operating Margin	-0.47%
Pretax Margin	-1.70%
Profit Margin	-0.02%
EBITDA Margin	1.55%
EBIT Margin	-0.47%
FCF Margin	n/a

Dividends & Yields

Keeps Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.54%
Shareholder Yield	-1.54%
Earnings Yield	-0.01%
FCF Yield	-7.77%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 20, 2020. It was a forward split with a ratio of 3.

Last Split Date	May 20, 2020
Split Type	Forward
Split Ratio	3

Scores

Keeps Biopharma has an Altman Z-Score of 1.94 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.94
Piotroski F-Score	2